Oncology News | pharmaphorum

News

BMS swoops on Mirati with $5.8bn takeover offer

After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in

News

FDA panel sceptical on Lumakras confirmatory data

An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that

News

Lilly takes POINT in radiopharma push

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.

News

Exscientia trims pipeline to focus on top cancer prospects

UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the

News

Takeda pulls Exkivity in US after failed confirmatory trial

Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result.

News

Aviva backs £1bn cancer hub in London

A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde

BMS swoops on Mirati with $5.8bn takeover offer

FDA panel sceptical on Lumakras confirmatory data

Lilly takes POINT in radiopharma push

Exscientia trims pipeline to focus on top cancer prospects

Takeda pulls Exkivity in US after failed confirmatory trial

Aviva backs £1bn cancer hub in London

NHS risks missing out on independent prescriber benefits

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks